{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T23:15:04Z","timestamp":1786403704093,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,7,21]],"date-time":"2017-07-21T00:00:00Z","timestamp":1500595200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s00259-017-3776-3","type":"journal-article","created":{"date-parts":[[2017,7,21]],"date-time":"2017-07-21T14:40:37Z","timestamp":1500648037000},"page":"2034-2041","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Predictive value of 18F-FDG PET\/CT in adults with T-cell lymphoblastic lymphoma: post hoc analysis of results from the GRAALL-LYSA LLO3 trial"],"prefix":"10.1007","volume":"44","author":[{"given":"St\u00e9phanie","family":"Becker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vermeulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-S\u00e9gol\u00e8ne","family":"Cottereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Boissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Lepretre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,21]]},"reference":[{"key":"3776_CR1","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/PPO.0b013e31826b1232","volume":"18","author":"CA Portell","year":"2012","unstructured":"Portell CA, Sweetenham JW. Adult lymphoblastic lymphoma. Cancer J. 2012;18:432\u20138.","journal-title":"Cancer J"},{"key":"3776_CR2","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.critrevonc.2010.12.003","volume":"79","author":"S Cortelazzo","year":"2011","unstructured":"Cortelazzo S, Ponzoni M, Ferreri AJ, Hoelzer D. Lymphoblastic lymphoma. Crit Rev Oncol Hematol. 2011;79:330\u201343.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3776_CR3","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/JCO.2015.61.5385","volume":"34","author":"S Lepretre","year":"2016","unstructured":"Lepretre S, Touzart A, Vermeulin T, Picquenot JM, Tanguy-Schmidt A, Salles G, et al. Pediatric-like acute lymphoblastic leukemia therapy in adults with lymphoblastic lymphoma: the GRAALL-LYSA LL03 study. J Clin Oncol. 2016;34:572\u201380.","journal-title":"J Clin Oncol"},{"key":"3776_CR4","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2014-01-547695","volume":"123","author":"K Beldjord","year":"2014","unstructured":"Beldjord K, Chevret S, Asnafi V, Huguet F, Boulland ML, Leguay T, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014;123:3739\u201349.","journal-title":"Blood"},{"key":"3776_CR5","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048\u201358.","journal-title":"J Clin Oncol"},{"key":"3776_CR6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","volume":"37","author":"R Boellaard","year":"2010","unstructured":"Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181\u2013200.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3776_CR7","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","volume":"41","author":"M Meignan","year":"2014","unstructured":"Meignan M, Sasanelli M, Casasnovas RO, Luminari S, Fioroni F, Coriani C, et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging. 2014;41:1113\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3776_CR8","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00259-014-2783-x","volume":"41","author":"S Kanoun","year":"2014","unstructured":"Kanoun S, Rossi C, Berriolo-Riedinger A, Dygai-Cochet I, Cochet A, Humbert O, et al. Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1735\u201343.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3776_CR9","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s00259-014-2822-7","volume":"41","author":"M Sasanelli","year":"2014","unstructured":"Sasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas RO, Biggi A, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:2017\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3776_CR10","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2967\/jnumed.107.042093","volume":"48","author":"C Lin","year":"2007","unstructured":"Lin C, Itti E, Haioun C, Petegnief Y, Luciani A, Dupuis J, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48:1626\u201332.","journal-title":"J Nucl Med"},{"key":"3776_CR11","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","volume":"50","author":"M Meignan","year":"2009","unstructured":"Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma. 2009;50:1257\u201360.","journal-title":"Leuk Lymphoma."},{"key":"3776_CR12","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3109\/0284186X.2014.889850","volume":"53","author":"F Ellin","year":"2014","unstructured":"Ellin F, Jerkeman M, Hagberg H, Relander T. Treatment outcome in T-cell lymphoblastic lymphoma in adults \u2013 a population-based study from the Swedish Lymphoma Registry. Acta Oncol. 2014;53:927\u201334.","journal-title":"Acta Oncol"},{"key":"3776_CR13","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.3892\/ol.2016.4806","volume":"12","author":"JH Park","year":"2016","unstructured":"Park JH, Pahk K, Kim S, Lim SM, Cheon GJ, Park YH, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography imaging of T-lymphoblastic lymphoma patients. Oncol Lett. 2016;12:1620\u20132.","journal-title":"Oncol Lett"},{"key":"3776_CR14","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","volume":"43","author":"NG Mikhaeel","year":"2016","unstructured":"Mikhaeel NG, Smith D, Dunn JT, Phillips M, Moller H, Fields PA, et al. Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43:1209\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3776_CR15","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1158\/1078-0432.CCR-16-0783","volume":"22","author":"AS Cottereau","year":"2016","unstructured":"Cottereau AS, Lanic H, Mareschal S, Meignan M, Vera P, Tilly H, et al. Molecular profile and FDG-PET metabolic volume at staging in DLBCL-response. Clin Cancer Res. 2016;22:3414\u20135.","journal-title":"Clin Cancer Res"},{"key":"3776_CR16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1179\/1607845415Y.0000000033","volume":"21","author":"M Xie","year":"2016","unstructured":"Xie M, Zhai W, Cheng S, Zhang H, Xie Y, He W. Predictive value of F-18 FDG PET\/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma. Hematology. 2016;21:99\u2013105.","journal-title":"Hematology"},{"key":"3776_CR17","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2967\/jnumed.113.130609","volume":"55","author":"C Rossi","year":"2014","unstructured":"Rossi C, Kanoun S, Berriolo-Riedinger A, Dygai-Cochet I, Humbert O, Legouge C, et al. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients. J Nucl Med. 2014;55:569\u201373.","journal-title":"J Nucl Med"},{"key":"3776_CR18","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/annonc\/mdw011","volume":"27","author":"AS Cottereau","year":"2016","unstructured":"Cottereau AS, Becker S, Broussais F, Casasnovas O, Kanoun S, Roques M, et al. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET\/CT in patients with peripheral T-cell lymphoma (PTCL). Ann Oncol. 2016;27:719\u201324.","journal-title":"Ann Oncol"},{"key":"3776_CR19","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/MNM.0000000000000496","volume":"37","author":"H Huang","year":"2016","unstructured":"Huang H, Xiao F, Han X, Zhong L, Zhong H, Xu L, et al. Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma. Nucl Med Commun. 2016;37:689\u201398.","journal-title":"Nucl Med Commun"},{"key":"3776_CR20","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s12185-011-0822-y","volume":"93","author":"D Chihara","year":"2011","unstructured":"Chihara D, Oki Y, Onoda H, Taji H, Yamamoto K, Tamaki T, et al. High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma. Int J Hematol. 2011;93:502\u20138.","journal-title":"Int J Hematol"},{"key":"3776_CR21","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1097\/MNM.0000000000000579","volume":"37","author":"JP Hwang","year":"2016","unstructured":"Hwang JP, Lim I, Byun BH, Kim BI, Choi CW, Lim SM. Prognostic value of SUVmax measured by pretreatment 18F-FDG PET\/CT in patients with primary gastric lymphoma. Nucl Med Commun. 2016;37:1267\u201372.","journal-title":"Nucl Med Commun"},{"key":"3776_CR22","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood-2016-03-703819","volume":"128","author":"AS Cottereau","year":"2016","unstructured":"Cottereau AS, Versari A, Chartier L, Dupuis J, Tarantino V, Casasnovas RO, et al. Low SUVmax measured on baseline FDG-PET\/CT and elevated \u03b22 microglobulin are negative predictors of outcome in high tumor burden follicular lymphoma treated by immunochemotherapy: a pooled analysis of three prospective studies. Blood. 2016;128:1101.","journal-title":"Blood"},{"key":"3776_CR23","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1200\/JCO.2012.48.5292","volume":"31","author":"A Trinquand","year":"2013","unstructured":"Trinquand A, Tanguy-Schmidt A, Ben Abdelali R, Lambert J, Beldjord K, Lengline E, et al. Toward a NOTCH1\/FBXW7\/RAS\/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol. 2013;31:4333\u201342.","journal-title":"J Clin Oncol"},{"key":"3776_CR24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1102160","volume":"306","author":"AP Weng","year":"2004","unstructured":"Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306:269\u201371.","journal-title":"Science"},{"key":"3776_CR25","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2967\/jnumed.108.057703","volume":"50","author":"E Itti","year":"2009","unstructured":"Itti E, Lin C, Dupuis J, Paone G, Capacchione D, Rahmouni A, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009;50:527\u201333.","journal-title":"J Nucl Med"},{"key":"3776_CR26","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12885-015-1193-1","volume":"15","author":"SH Jung","year":"2015","unstructured":"Jung SH, Ahn JS, Kim YK, Kweon SS, Min JJ, Bom HS, et al. Prognostic significance of interim PET\/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma. BMC Cancer. 2015;15:198.","journal-title":"BMC Cancer"},{"key":"3776_CR27","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1182\/blood-2005-01-0272","volume":"106","author":"C Haioun","year":"2005","unstructured":"Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106:1376\u201381.","journal-title":"Blood"},{"key":"3776_CR28","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","volume":"25","author":"A Gallamini","year":"2007","unstructured":"Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746\u201352.","journal-title":"J Clin Oncol"},{"key":"3776_CR29","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ajh.24287","volume":"91","author":"I Cunningham","year":"2016","unstructured":"Cunningham I, Kohno B. 18 FDG-PET\/CT: 21st century approach to leukemic tumors in 124 cases. Am J Hematol. 2016;91:379\u201384.","journal-title":"Am J Hematol"},{"key":"3776_CR30","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.3109\/10428194.2010.529208","volume":"51","author":"M Meignan","year":"2010","unstructured":"Meignan M, Gallamini A, Haioun C, Polliack A. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma. 2010;51:2171\u201380.","journal-title":"Leuk Lymphoma"},{"key":"3776_CR31","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00277-011-1357-2","volume":"91","author":"MK Song","year":"2012","unstructured":"Song MK, Chung JS, Shin HJ, Lee SM, Lee SE, Lee HS, et al. Clinical significance of metabolic tumor volume by PET\/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol. 2012;91:697\u2013703.","journal-title":"Ann Hematol"},{"key":"3776_CR32","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00259-013-2443-6","volume":"40","author":"CY Kim","year":"2013","unstructured":"Kim CY, Hong CM, Kim DH, Son SH, Jeong SY, Lee SW, et al. Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on 18F-FDG PET\/CT in patients with extranodal NK\/T-cell lymphoma. Eur J Nucl Med Mol Imaging. 2013;40:1321\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3776_CR33","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/sj.leu.2404156","volume":"20","author":"E Jabbour","year":"2006","unstructured":"Jabbour E, Koscielny S, Sebban C, Peslin N, Patte C, Gargi T, et al. High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL). Leukemia. 2006;20:814\u20139.","journal-title":"Leukemia"},{"key":"3776_CR34","doi-asserted-by":"crossref","first-page":"38884","DOI":"10.18632\/oncotarget.9144","volume":"7","author":"MY Zhu","year":"2016","unstructured":"Zhu MY, Wang H, Huang CY, Xia ZJ, Chen XQ, Geng QR, et al. A childhood chemotherapy protocol improves overall survival among adults with T-lymphoblastic lymphoma. Oncotarget. 2016;7:38884\u201391.","journal-title":"Oncotarget"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-017-3776-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-017-3776-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-017-3776-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T08:23:19Z","timestamp":1569918199000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-017-3776-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,21]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["3776"],"URL":"https:\/\/doi.org\/10.1007\/s00259-017-3776-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,21]]}}}